IL17A and type 1 diabetes mellitus: An additional study found that, among PBMCs from type 1 diabetes (T1D) patients, in vitro activation of islet antigen-specific T cells was inhibited by MSC EVs, decreasing the frequency of Th17 cells and IL-17 levels via a mechanism involving TGF-β and PGE2.